Manila Times Business
NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO
CHICAGO, May 31, 2026 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent malignant glioma as Rapid Oral presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO 2026). ASCO is one of the leading global oncology conferences. With over 8,500 submissions, abstracts selected for oral presentation represents studies of significant scientific and clinical interests. "W
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
VP Sara leads Robredo in May presidential preference survey
1h ago
US military fires on Gambia-flagged ship violating Iran blockade
1h ago
SlimTide Truth Revealed (2026 Official Website Risk Warning) Avoid Hidden Fees & Fake Complaints
2h ago
Trump calls for replacing US 250th concerts with MAGA rally
2h ago